[Pefloxacin mesylate--clinical effectiveness in various forms of infectious-inflammatory diseases].

Pefloxacin mesylate is a broad spectrum fluoroquinolone active against pathogens with multiple resistance. Due to its high therapeutic efficacy (at last 90 per cent) and good tolerance pefloxacin mesylate is considered as the most promising drug in the therapy of severe infections and infections difficult for the treatment such as wound infection, meningitis and particularly perilous infections. Prolonged pharmacokinetics and high bioavailability of the drug provided its administration in the treatment of in- and outpatients with severe infection twice a day in a daily dose of 0.

[Reaferon in the treatment of hemorrhagic fever with the renal syndrome].

Ninety six patients with hemorrhagic fever and the renal syndrome were followed up. Reaferon was included into the complex therapy of 57 cases. The drug was administered intramuscularly in a dose of 2 x 10(6) IU twice a day for 5 days.